The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.

In August 2022, the FDA approved darolutamide in combination with docetaxel for the treatment of patients with mHSPC. 3 The ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...

The expansion in indications comes after the company’s Phase III trial saw the treatment extending survival in patients with ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Toward a Framework to Assess the Financial and Economic Burden of Cervical Cancer in Low- and Middle-Income Countries: A Systematic Review The Brazilian Public Health System (BPHS) serves ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Metastatic castration-resistant prostate cancer (mCRPC) and its precursor, metastatic hormone sensitive prostate cancer (mHSPC), are advanced forms of the condition that don’t respond to initial ...

At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) ...